MA31936B1 - Nouveaux composes et nouvelles compositions et leurs procedes d'utilisation - Google Patents

Nouveaux composes et nouvelles compositions et leurs procedes d'utilisation

Info

Publication number
MA31936B1
MA31936B1 MA32950A MA32950A MA31936B1 MA 31936 B1 MA31936 B1 MA 31936B1 MA 32950 A MA32950 A MA 32950A MA 32950 A MA32950 A MA 32950A MA 31936 B1 MA31936 B1 MA 31936B1
Authority
MA
Morocco
Prior art keywords
novel
methods
compounds
compositions
novel compounds
Prior art date
Application number
MA32950A
Other languages
Arabic (ar)
English (en)
Inventor
Barry D Quart
Jean-Luc Girardet
Esmir Gunic
Li-Tain Yeh
Original Assignee
Ardea Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40679222&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA31936(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ardea Biosciences Inc filed Critical Ardea Biosciences Inc
Publication of MA31936B1 publication Critical patent/MA31936B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/28—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/02—Acyclic radicals

Abstract

La présente invention concerne des composés utiles dans la modulation des taux d'acide urique dans le sang, des formulations les comprenant et leurs procédés d'utilisation. Dans certains modes de réalisation, les composés décrits ici sont utilisés pour le traitement ou la prévention de troubles liés à des taux aberrants d'acide urique.
MA32950A 2007-11-27 2010-06-25 Nouveaux composes et nouvelles compositions et leurs procedes d'utilisation MA31936B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US99057407P 2007-11-27 2007-11-27
US9438808P 2008-09-04 2008-09-04
PCT/US2008/084988 WO2009070740A2 (fr) 2007-11-27 2008-11-26 Nouveaux composés et nouvelles compositions et leurs procédés d'utilisation

Publications (1)

Publication Number Publication Date
MA31936B1 true MA31936B1 (fr) 2010-12-01

Family

ID=40679222

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32950A MA31936B1 (fr) 2007-11-27 2010-06-25 Nouveaux composes et nouvelles compositions et leurs procedes d'utilisation

Country Status (36)

Country Link
US (8) US8084483B2 (fr)
EP (2) EP2217577B1 (fr)
JP (3) JP5099794B2 (fr)
KR (2) KR101291643B1 (fr)
CN (3) CN101918377A (fr)
AR (1) AR069753A1 (fr)
AU (2) AU2008329673C1 (fr)
BR (1) BRPI0819847B1 (fr)
CA (1) CA2706858C (fr)
CL (1) CL2008003529A1 (fr)
CY (1) CY2019010I2 (fr)
DK (1) DK2217577T3 (fr)
EA (2) EA201270666A1 (fr)
EC (1) ECSP10010310A (fr)
ES (1) ES2513390T3 (fr)
HK (2) HK1180337A1 (fr)
HR (1) HRP20140950T1 (fr)
HU (1) HUS1900009I1 (fr)
IL (1) IL205974A (fr)
LT (1) LTPA2019003I1 (fr)
LU (1) LUC00103I2 (fr)
MA (1) MA31936B1 (fr)
ME (2) ME01294B (fr)
MX (1) MX2010005776A (fr)
MY (1) MY147370A (fr)
NO (1) NO2016016I1 (fr)
NZ (4) NZ601786A (fr)
PL (1) PL2217577T3 (fr)
PT (1) PT2217577E (fr)
RS (1) RS53569B1 (fr)
SG (1) SG183721A1 (fr)
SI (1) SI2217577T1 (fr)
TN (1) TN2010000237A1 (fr)
TW (1) TWI415840B (fr)
WO (1) WO2009070740A2 (fr)
ZA (1) ZA201003769B (fr)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007050087A1 (fr) 2004-08-25 2007-05-03 Ardea Biosciences, Inc. Acides N[S(4-aryltriazol-3-yl)α-mercaptoacétyl]-p-aminobenzoïques EN TANT QU'INHIBITEURS DE TRANSCRIPTASE INVERSE DE VIH
EA015846B1 (ru) 2004-08-25 2011-12-30 Ардеа Байосайенсиз, Инк. 2-[5-бром-4-(4-циклопропилнафталин-1-ил)-4н-[1,2,4]триазол-3-илсульфанил]уксусная кислота и ее метиловый эфир
NZ601786A (en) 2007-11-27 2014-02-28 Ardea Biosciences Inc Novel compounds and compositions and methods of use
WO2010028189A2 (fr) * 2008-09-04 2010-03-11 Ardea Biosciences, Inc. Composés, compositions, et procédés d'utilisation, permettant de moduler les taux d'acide urique
US8173690B2 (en) * 2008-09-04 2012-05-08 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
US8242154B2 (en) * 2008-09-04 2012-08-14 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
WO2010048592A1 (fr) * 2008-10-24 2010-04-29 Ardea Biosciences, Inc. Compositions comprenant l'acide 4-(2-(5-bromo-4-(1- cyclopropylnaphtalén-4-yl)-4h-1,2,4-triazol-3-ylthio)acétamido-3- chlorobenzoïque et ses sels de qualité pharmaceutique
AR073964A1 (es) * 2008-10-24 2010-12-15 Ardea Biosciences Inc Composiciones que comprenden acido 4-(2-(5-bromo-4-(1-ciclopropilnaftalen -4-il) -4h- 1,2,4-triazol-3-il tio ) acetamido)-3-clorobenzoico y sus sales farmaceuticamente aceptables y metodos de preparacion y uso delos mismos
WO2010071865A1 (fr) 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Compositions pharmaceutiques et procédés de traitement de l'hyperuricémie et des troubles associés
US20100160351A1 (en) * 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
WO2010135536A2 (fr) 2009-05-20 2010-11-25 Ardea Biosciences, Inc. Procédés pour moduler des taux d'acide urique
EP2432774A4 (fr) * 2009-05-20 2013-01-02 Ardea Biosciences Inc Composés, compositions et procédés pour moduler des taux d'acide urique
BR112012016795A2 (pt) * 2010-01-08 2020-09-01 Ardea Biosciences Inc. formas polimórficas, cristalinas e de mesofase de 2-(5- bromo -4-(4-ciclopropilnaftalen-1-il)-4h-1,2,34-triazol-3iltio) acetato de sódio e seus usos
CA2794798C (fr) * 2010-03-30 2017-05-30 Ardea Biosciences, Inc. Traitement de la goutte
PL2582683T3 (pl) * 2010-06-15 2018-08-31 Ardea Biosciences, Inc. Leczenie dny moczanowej i hiperurykemii
AR081930A1 (es) 2010-06-16 2012-10-31 Ardea Biosciences Inc Compuestos de tioacetato
WO2011159840A2 (fr) 2010-06-16 2011-12-22 Ardea Biosciences, Inc. Phénylthioacétates, compositions et procédés d'application
CN103249417A (zh) 2010-10-15 2013-08-14 阿迪亚生命科学公司 用于治疗高尿酸血症及相关疾病的方法
US20130225830A1 (en) * 2010-10-28 2013-08-29 Mapi Pharma Limited Polymorphs of febuxostat
KR101541629B1 (ko) * 2010-12-30 2015-08-03 아디아 바이오사이언스즈 인크. 2-(5-브로모-4-(4-사이클로프로필나프탈렌-1-일)-4ｈ-1,2,4-트리아졸-3-일티오)아세트산의 다형 및 이의 용도
WO2012122532A2 (fr) * 2011-03-09 2012-09-13 Biocryst Pharmaceuticals, Inc. Compositions et méthodes de traitement de l'hyperuricémie
JP5964952B2 (ja) * 2011-05-24 2016-08-03 アルデア バイオサイエンシーズ インク． 高血圧症と高尿酸血症
EP2567959B1 (fr) 2011-09-12 2014-04-16 Sanofi Dérivés d'amide d'acide 6-(4-hydroxy-phényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
EP3501520A1 (fr) 2011-11-03 2019-06-26 Ardea Biosciences, Inc. Composé de pyridine 3,4-disubstituée, procédés d'utilisation et compositions le comprenant
MX354846B (es) * 2011-11-04 2018-03-22 Cymabay Therapeutics Inc Metodos para tratar gota en sub-poblaciones de pacientes.
US9060987B2 (en) 2011-11-04 2015-06-23 Cymabay Therapeutics, Inc. Methods for treating gout flares
US9023856B2 (en) 2011-11-04 2015-05-05 Cymabay Therapeutics, Inc. Methods for treating hyperuricemia in patients with gout using halofenate or halogenic acid and a second urate-lowering agent
CN104066324A (zh) * 2011-11-04 2014-09-24 西玛贝医药公司 治疗痛风急性发作的方法
EP2808018B1 (fr) * 2012-01-27 2018-03-14 Teijin Pharma Limited Agent thérapeutique pour le diabète
AR091651A1 (es) * 2012-07-03 2015-02-18 Ardea Biosciences Inc Elaboracion de acido 2-(5-bromo-4-(4-ciclopropilnaftalen-1-il)-4h-1,2,4-triazol-3-iltio)acetico
NO2944633T3 (fr) * 2012-11-14 2018-06-30
CN102973530B (zh) * 2012-12-14 2016-08-03 贵州信邦制药股份有限公司 一种非布索坦双层肠溶片剂及其制备方法
DK2998296T3 (en) 2013-05-13 2018-05-22 Shanghai hengrui pharmaceutical co ltd CYCLOYLIC ACID DERIVATIVE, PROCEDURE FOR PREPARING THEREOF AND PHARMACEUTICAL USE THEREOF
WO2014198241A1 (fr) * 2013-06-14 2014-12-18 Sunshine Lake Pharma Co., Ltd. Dérivés de thio-1,2,4-triazole et leur procédé de préparation
CN103524440B (zh) * 2013-10-15 2015-09-09 苏州鹏旭医药科技有限公司 痛风治疗药Lesinurad的制备方法及Lesinurad中间体
CN104447589B (zh) * 2013-11-20 2017-01-11 广东东阳光药业有限公司 一种尿酸调节剂的制备方法及其中间体
CN103613552A (zh) * 2013-12-02 2014-03-05 苏州晶云药物科技有限公司 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1，2，4-***-3-基硫基)乙酸钠的新晶型及其制备方法
CN103588716A (zh) * 2013-11-22 2014-02-19 苏州晶云药物科技有限公司 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1，2，4-***-3-基硫基)乙酸的新晶型及其制备方法
ES2704198T3 (es) * 2013-11-22 2019-03-14 Crystal Pharmatech Co Ltd Formas cristalinas de lesinurad
CN103626710A (zh) * 2013-12-20 2014-03-12 苏州晶云药物科技有限公司 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1，2，4-***-3-基硫基)乙酸的共晶及其制备方法
US9969701B2 (en) * 2013-12-20 2018-05-15 Crystal Pharmatech Co., Ltd. Salts and co-crystals of lesinurad
CN103755651A (zh) * 2013-12-23 2014-04-30 苏州晶云药物科技有限公司 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1，2，4-***-3-基硫基)乙酸的盐的新晶型及其制备方法
CN105294585B (zh) * 2014-07-02 2019-02-12 成都海创药业有限公司 一种治疗痛风的化合物
CN104068288B (zh) * 2014-07-25 2016-08-24 许伟琦 一种防***的饲料添加剂
CN104326993B (zh) * 2014-10-27 2016-08-17 张远强 一种硝基取代三氮唑亚磺酰丙二酸类化合物、其制备方法及用途
CN104326995A (zh) * 2014-10-27 2015-02-04 张远强 一种腈基取代的三氮唑丙二酸类化合物、其制备方法及用途
CN104370841B (zh) * 2014-10-27 2016-07-13 张远强 三氮唑亚磺酰丙二酸类化合物、其制备方法及用途
CN104326998B (zh) * 2014-10-27 2016-08-17 张远强 苯基取代的三氮唑丙二酸类化合物、其制备方法及用途
CN104341364A (zh) * 2014-10-27 2015-02-11 张远强 三氮唑丙二酸类化合物、其制备方法及用途
CN104370842B (zh) * 2014-10-27 2016-07-13 张远强 苯基取代的三氮唑磺酰丙二酸类化合物、其制备方法及用途
CN104327000B (zh) * 2014-10-27 2016-08-17 张远强 苯基取代的三氮唑亚磺酰丙二酸类化合物、其制备方法及用途
CN104341365A (zh) * 2014-10-27 2015-02-11 张远强 卤代三氮唑丙二酸类化合物、其制备方法及用途
CN104341362B (zh) * 2014-10-27 2016-07-13 张远强 三氮唑磺酰丙二酸类化合物、其制备方法及用途
CN104341363B (zh) * 2014-10-27 2016-08-17 张远强 一种硝基取代的三氮唑磺酰丙二酸类化合物、其制备方法及用途
CN104326996A (zh) * 2014-10-27 2015-02-04 张远强 一种硝基取代三氮唑丙二酸类化合物、其制备方法及用途
CN104326994A (zh) * 2014-10-27 2015-02-04 张远强 一种腈基取代的三氮唑磺酰丙二酸类化合物、其制备方法及用途
CN104529848A (zh) * 2014-11-10 2015-04-22 安徽万邦医药科技有限公司 一种1-环丙基-4-异硫氰酰基萘的合成方法
EP3915542B1 (fr) 2014-12-23 2023-11-22 Dyve Biosciences, Inc. Formulations pour l'administration transdermique
ES2865182T3 (es) 2014-12-29 2021-10-15 Nippon Chemiphar Co Inhibidor de URAT1
CN109053608A (zh) * 2015-02-17 2018-12-21 华润赛科药业有限责任公司 一种旋光纯的硫代乙酸类化合物、其药物组合物和用途
CN105622531A (zh) * 2015-04-03 2016-06-01 南京明德新药研发股份有限公司 轴手性异构体及其制备方法和制药用途
CN104710374A (zh) * 2015-04-14 2015-06-17 安徽省逸欣铭医药科技有限公司 一种痛风新化合物及制备方法、用途及其药物制剂
CN106187926B (zh) 2015-04-30 2018-11-27 天津药物研究院有限公司 含二芳基甲烷结构的羧酸类urat1抑制剂、制备方法及其在高尿酸血症和痛风治疗上的用途
WO2016203436A1 (fr) * 2015-06-19 2016-12-22 Dr. Reddy's Laboratories Limited Dispersions amorphes et solides amorphes de lesinurad et leur préparation
EP3112334A1 (fr) 2015-06-29 2017-01-04 DPx Fine Chemicals Austria GmbH & CoKG Procédé de fabrication de 1-cyclopropyl-naphthalènes
CN104987311A (zh) * 2015-06-30 2015-10-21 安徽万邦医药科技有限公司 一种[4-(4-环丙基萘-1-基)-5-硝基- 4h-[1,2,4]***-3-基硫烷基]-乙酸乙酯的制备方法及其中间体(5-硝基-4h-[1,2,4]***-3-基硫基)-乙酸乙酯
CN105017168A (zh) * 2015-07-01 2015-11-04 安徽万邦医药科技有限公司 一种[5-溴-4-(4-环丙基萘-1-基)-4h-[1,2,4]***-3-基硫烷基]-乙酸甲酯的新制备方法
CN105153056A (zh) * 2015-07-01 2015-12-16 安徽万邦医药科技有限公司 一种[5-溴-4-(4-环丙基萘-1-基)-4h-[1,2,4]***-3-基硫烷基]-乙酸甲酯的新制备方法
US10682372B2 (en) * 2015-08-26 2020-06-16 Stagen Co., Ltd. Intracellular ATP enhancer
WO2017036884A1 (fr) 2015-08-28 2017-03-09 Sandoz Ag Co-cristal de lésinurad, forme libre/ester éthylique de lésinurad
CN105301126B (zh) * 2015-10-10 2021-02-12 大道隆达（北京）医药科技发展有限公司 一种托匹司他有关物质的分析方法
EP3380970B1 (fr) * 2015-11-24 2023-01-04 Sanford Burnham Prebys Medical Discovery Institute Nouveaux dérivés azolés comme agoniste du récepteur de l'apéline
ES2911284T3 (es) * 2015-12-28 2022-05-18 Shanghai Fochon Pharmaceutical Co Ltd Derivados de indolizina, composición y métodos de uso
US20170319552A1 (en) * 2016-02-24 2017-11-09 Ardea Biosciences, Inc. Atropisomers of triazole derivative
CN107176930B (zh) * 2016-03-11 2020-12-01 广东赛烽医药科技有限公司 2-[5-溴-4-(4-氟代环丙基萘-1-基)-4h-1，2，4-***-3-基硫基]乙酸化合物及其应用
CN107337649B (zh) * 2016-04-29 2020-10-16 四川科伦药物研究院有限公司 一种乙酸钠水合物无定型及其制备方法和用途
CN109790155B (zh) 2016-05-23 2022-02-18 东宝紫星(杭州)生物医药有限公司 噻吩化合物及其合成方法和其在医药上的应用
CN106074540B (zh) * 2016-06-10 2018-10-16 江西博屾医疗器械有限公司 一种用于高尿酸血症治疗的药物组合物及其应用
DK3473617T3 (da) * 2016-06-17 2022-11-28 Medshine Discovery Inc Halogeneret forbindelse og aksiale, chirale isomerer deraf
CN105943552A (zh) * 2016-06-17 2016-09-21 王枝宝 一种氢氧化钾的医药用途
CN106083847B (zh) * 2016-08-03 2018-10-30 山东大学 一种咪唑并吡啶巯乙酸类衍生物及其制备方法与应用
EP3281941B1 (fr) 2016-08-11 2019-07-24 Zentiva K.S. Procédé de préparation d'acide 2-(5-bromo-4-(1-cyclopropylnaphtalén-4-yl)-4h-1,2,4-triazol-3-ythio) acétique
CZ2016611A3 (cs) * 2016-09-30 2018-05-09 Zentiva, K.S. Způsob výroby 2-(5-brom-4-(1-cyklopropylnaftalen-4-yl)-4H-1,2,4-triazol-3-ylthio)octové kyseliny - lesinuradu
CN108014108A (zh) * 2016-11-03 2018-05-11 江苏万邦生化医药股份有限公司 lesinurad或其医药上可接受的盐在制备治疗或预防库欣综合征的药物中的应用
WO2018085932A1 (fr) 2016-11-10 2018-05-17 Apotex Inc. Nouvelles formes cristallines du lésinurad
EP3538151A4 (fr) 2016-11-11 2020-06-10 Whitehead Institute for Biomedical Research Milieu de type plasma humain
CN108164471B (zh) * 2016-12-07 2019-09-13 浙江京新药业股份有限公司 Lesinurad衍生物及其制备方法和用途
US10351537B2 (en) 2017-03-10 2019-07-16 Apotex Inc. Processes for the preparation of lesinurad and intermediates thereof
EP3315494A1 (fr) 2017-04-19 2018-05-02 Química Sintética, S.A. Forme amorphe de lésinurad et ses procédés de préparation
CN108947919B (zh) * 2017-05-17 2023-05-02 上海奥博生物医药股份有限公司 一种抗痛风药Lesinurad的新型制备方法及其关键中间体
US10538808B2 (en) 2017-05-26 2020-01-21 Vibrant Holdings, Llc Photoactive compounds and methods for biomolecule detection and sequencing
EP4324460A3 (fr) 2017-09-15 2024-04-24 Dyve Biosciences, Inc. Bicarbonate de sodium pour utilisation dans le traitement de la goutte et de troubles associés
KR102246619B1 (ko) 2017-11-23 2021-04-30 메드샤인 디스커버리 아이엔씨. Urat1 억제제의 결정형 및 그의 제조 방법
EP3498697A1 (fr) 2017-12-12 2019-06-19 Química Sintética, S.A. Nouveaux sels et polymorphes de lesinurad
WO2019114838A1 (fr) * 2017-12-15 2019-06-20 南京明德新药研发股份有限公司 Cristal et sel de composé de 4-(naphtalén-1-yl)-4h-1,2,4-triazole et son procédé de préparation
CN109369783B (zh) * 2018-11-30 2021-09-10 昆明医科大学 一种多肽rdp1及其提纯方法与应用
CN111320588B (zh) * 2018-12-14 2024-02-09 上海奥博生物医药股份有限公司 一种纯化Lesinurad的方法

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2006101A (en) 1932-07-05 1935-06-25 Meaf Mach En Apparaten Fab Nv Reversing mechanism for dry gas meters
US4198513A (en) 1970-09-25 1980-04-15 Merck & Co., Inc. 1,2,4-Triazoles
NL7112373A (fr) * 1970-09-25 1972-03-28
JPS5641637B2 (fr) 1973-11-26 1981-09-29
US4889868A (en) 1984-12-20 1989-12-26 Rorer Pharmaceutical Corporation Bis-imidazolinoamino derivatives as antiallergy compounds
US5260322A (en) * 1990-10-08 1993-11-09 Merck & Co., Inc. Angiotension II antagonists in the treatment of hyperuricemia
US6832996B2 (en) 1995-06-07 2004-12-21 Arthrocare Corporation Electrosurgical systems and methods for treating tissue
JPH07215940A (ja) 1994-01-27 1995-08-15 Torii Yakuhin Kk 抗ウイルス活性を有する化合物
US5945425A (en) 1994-04-29 1999-08-31 G.D. Searle & Co. Method of using (H+ /K+)ATPase inhibitors as antiviral agents
JP3964478B2 (ja) 1995-06-30 2007-08-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬
US6017925A (en) 1997-01-17 2000-01-25 Merck & Co., Inc. Integrin antagonists
US6245817B1 (en) 1997-02-14 2001-06-12 Bayer Corporation NPY5 receptor antagonists and methods for using same
EP0910565A1 (fr) 1997-02-14 1999-04-28 Bayer Corporation Derives amides actifs comme antagonistes selectifs du recepteur du neuropeptide y
BRPI9909191B8 (pt) 1998-03-27 2021-07-06 Janssen Pharmaceutica Nv derivados de pirimidina inibidores do hiv, seu uso e composição farmacêutica que os compreende
DK1129096T3 (da) 1998-11-12 2003-09-15 Neurocrine Biosciences Inc CRF-receptorantagonister og fremgangsmåder, der er relateret dertil
WO2000037471A1 (fr) 1998-12-23 2000-06-29 Neurogen Corporation 2-amino-9-alkylpurines: ligands pour recepteurs cerebraux gaba
US6593077B2 (en) 1999-03-22 2003-07-15 Special Materials Research And Technology, Inc. Method of making thin films dielectrics using a process for room temperature wet chemical growth of SiO based oxides on a substrate
US6624194B1 (en) * 1999-06-04 2003-09-23 Metabolex, Inc. Use of (−) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
MXPA03007883A (es) 2001-03-02 2003-12-04 Smithkline Beecham Corp Benzofenonas como inhibidores de transcriptasa inversa.
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
CN1561340B (zh) 2002-01-28 2012-05-23 株式会社富士药品 1,2,4-***类化合物
JP2005529923A (ja) 2002-05-13 2005-10-06 イーライ・リリー・アンド・カンパニー 肥満および糖尿病の治療におけるメラニン凝集ホルモンアンタゴニストとして使用するための多環式化合物
BR0313747A (pt) 2002-08-23 2005-06-21 Ribapharm Inc Inibidores de transcriptase reversa de não-nucleosìdeo
US7642277B2 (en) 2002-12-04 2010-01-05 Boehringer Ingelheim International Gmbh Non-nucleoside reverse transcriptase inhibitors
MXPA05008364A (es) 2003-02-07 2005-11-04 Janssen Pharmaceutica Nv Derivados de pirimidina para la prevencion de una infeccion por vih.
US8026245B2 (en) 2003-09-25 2011-09-27 Janssen Pharmaceutica N.V. HIV replication inhibiting purine derivatives
US20080031901A1 (en) * 2004-09-24 2008-02-07 Abbott Laboratories Sustained release monoeximic formulations of opioid and nonopioid analgesics
JP4660376B2 (ja) 2003-11-14 2011-03-30 株式会社ヒューマンセルシステムズ 血管障害や高血圧症の治療・予防剤、及びそのスクリーニング方法
EP1694323A4 (fr) 2003-12-19 2009-05-13 Elixir Pharmaceuticals Inc Procedes de traitement d'un trouble
CN1934095A (zh) * 2004-03-08 2007-03-21 惠氏公司 离子通道调节剂
EP1723123A4 (fr) 2004-03-08 2009-12-02 Wyeth Corp Modulateurs de canaux ioniques
MXPA06013581A (es) * 2004-05-25 2007-03-15 Metabolex Inc Triazoles sustituidos como moduladores de ppar y metodos para su preparacion.
US20060013556A1 (en) 2004-07-01 2006-01-19 Thomas Poslinski Commercial information and guide
EA015846B1 (ru) 2004-08-25 2011-12-30 Ардеа Байосайенсиз, Инк. 2-[5-бром-4-(4-циклопропилнафталин-1-ил)-4н-[1,2,4]триазол-3-илсульфанил]уксусная кислота и ее метиловый эфир
WO2007050087A1 (fr) 2004-08-25 2007-05-03 Ardea Biosciences, Inc. Acides N[S(4-aryltriazol-3-yl)α-mercaptoacétyl]-p-aminobenzoïques EN TANT QU'INHIBITEURS DE TRANSCRIPTASE INVERSE DE VIH
GB0422057D0 (en) 2004-10-05 2004-11-03 Astrazeneca Ab Novel compounds
US7947707B2 (en) * 2005-10-07 2011-05-24 Kissei Pharmaceutical Co., Ltd. Nitrogenated heterocyclic compound and pharmaceutical composition comprising the same
WO2007077042A1 (fr) 2006-01-06 2007-07-12 Topotarget Switzerland Sa Nouveau procede de traitement de la goutte ou la pseudogoutte
JP2009530399A (ja) 2006-03-22 2009-08-27 シンデクサ ファーマシューティカルズ コーポレーション Ｅｒストレスに関連する疾病の治療のための化合物及び方法
CA2653217A1 (fr) 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Procede pour traiter des troubles proliferants associes a des produits protooncogenes
WO2007140002A2 (fr) 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Méthode pour traiter un lymphome non hodgkinien
US7687526B2 (en) 2006-09-07 2010-03-30 Amgen Inc. Benzo-fused compounds for use in treating metabolic disorders
EP1939181A1 (fr) 2006-12-27 2008-07-02 sanofi-aventis Carboxamides hétérocycliques et leur utilisation pour la stimulation de l'expression de la NO synthase
BRPI0806608A2 (pt) 2007-01-19 2011-09-06 Takeda Pharmaceuticals North America Inc métodos para prevenir ou reduzir o número de surtos agudos de gota utilizando inibidores xantina oxidoredutase e agentes anti-inflamatórios
NZ601786A (en) 2007-11-27 2014-02-28 Ardea Biosciences Inc Novel compounds and compositions and methods of use
US8242154B2 (en) 2008-09-04 2012-08-14 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
US8173690B2 (en) 2008-09-04 2012-05-08 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
WO2010048592A1 (fr) 2008-10-24 2010-04-29 Ardea Biosciences, Inc. Compositions comprenant l'acide 4-(2-(5-bromo-4-(1- cyclopropylnaphtalén-4-yl)-4h-1,2,4-triazol-3-ylthio)acétamido-3- chlorobenzoïque et ses sels de qualité pharmaceutique
WO2010071865A1 (fr) 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Compositions pharmaceutiques et procédés de traitement de l'hyperuricémie et des troubles associés
JP5964952B2 (ja) 2011-05-24 2016-08-03 アルデア バイオサイエンシーズ インク． 高血圧症と高尿酸血症

Also Published As

Publication number Publication date
US20170281601A1 (en) 2017-10-05
DK2217577T3 (da) 2014-10-20
AU2012203172A1 (en) 2012-06-21
EP2217577B1 (fr) 2014-08-06
ME01996B (me) 2015-05-20
US8283369B2 (en) 2012-10-09
MX2010005776A (es) 2010-08-31
TN2010000237A1 (en) 2011-11-11
US20120164222A1 (en) 2012-06-28
CN102643241A (zh) 2012-08-22
SI2217577T1 (sl) 2014-11-28
WO2009070740A3 (fr) 2009-08-13
NZ595035A (en) 2012-11-30
US8357713B2 (en) 2013-01-22
SG183721A1 (en) 2012-09-27
KR101411806B1 (ko) 2014-06-24
RS53569B1 (en) 2015-02-27
EA018193B1 (ru) 2013-06-28
AR069753A1 (es) 2010-02-17
AU2012203172B2 (en) 2013-10-10
ES2513390T3 (es) 2014-10-27
CN103058944B (zh) 2015-08-05
NO2016016I2 (no) 2016-08-17
AU2008329673B2 (en) 2012-04-12
EP2217577A2 (fr) 2010-08-18
HUS1900009I1 (hu) 2019-03-28
ECSP10010310A (es) 2010-07-30
EA201270666A1 (ru) 2012-12-28
JP2012184234A (ja) 2012-09-27
KR101291643B1 (ko) 2013-08-01
JP5905934B2 (ja) 2016-04-20
TWI415840B (zh) 2013-11-21
JP5099794B2 (ja) 2012-12-19
US8546437B2 (en) 2013-10-01
HK1180337A1 (en) 2013-10-18
KR20120084787A (ko) 2012-07-30
US20190142805A1 (en) 2019-05-16
US8084483B2 (en) 2011-12-27
LTPA2019003I1 (lt) 2019-02-25
MY147370A (en) 2012-11-30
US10183012B2 (en) 2019-01-22
NZ601774A (en) 2013-07-26
NZ601786A (en) 2014-02-28
WO2009070740A2 (fr) 2009-06-04
LUC00103I1 (fr) 2019-02-19
US20140005136A1 (en) 2014-01-02
EP2842948A1 (fr) 2015-03-04
EA018193B3 (ru) 2014-07-30
ZA201003769B (en) 2011-02-23
BRPI0819847A2 (pt) 2020-10-06
NZ585583A (en) 2011-09-30
CA2706858A1 (fr) 2009-06-04
US20110268801A1 (en) 2011-11-03
CN103058944A (zh) 2013-04-24
LUC00103I2 (fr) 2019-12-27
AU2008329673C1 (en) 2012-10-25
NO2016016I1 (no) 2016-08-17
US20090197825A1 (en) 2009-08-06
CA2706858C (fr) 2013-12-24
PT2217577E (pt) 2014-10-20
BRPI0819847B1 (pt) 2022-01-11
US20160221970A1 (en) 2016-08-04
CY2019010I1 (el) 2019-11-27
CN101918377A (zh) 2010-12-15
JP2011504935A (ja) 2011-02-17
IL205974A (en) 2015-03-31
CN102643241B (zh) 2015-01-21
IL205974A0 (en) 2010-11-30
HRP20140950T1 (hr) 2014-12-05
HK1172326A1 (en) 2013-04-19
PL2217577T3 (pl) 2015-01-30
US20110293719A1 (en) 2011-12-01
CY2019010I2 (el) 2019-11-27
TW200927733A (en) 2009-07-01
EP2217577A4 (fr) 2010-12-08
KR20100085195A (ko) 2010-07-28
JP2014196373A (ja) 2014-10-16
AU2008329673A1 (en) 2009-06-04
CL2008003529A1 (es) 2009-11-27
EA201000897A1 (ru) 2010-12-30
ME01294B (fr) 2013-06-20

Similar Documents

Publication Publication Date Title
MA31936B1 (fr) Nouveaux composes et nouvelles compositions et leurs procedes d'utilisation
TNSN07070A1 (fr) Composes aminoheteroaryliques enantiomeriquement purs servant d'inhibiteurs de proteine-kinases
DE602004030222D1 (de) 2-oxo-1,3,5-perhydrotriazapinderivate, die sich zur behandlung von hyperproliferativen, angiogenen und entzündlichen erkrankungen eignen
MA34147B1 (fr) Composes tricycliques fusionnes de silyle et leurs methodes d'utilisation dans le cadre du traitement de maladies virales
MXPA03011484A (es) Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades.
MA29480B1 (fr) Pyrrolopyridines substitues, compositions les contenant, procede de fabrication et utilisation
MA29411B1 (fr) 1h-quinazoline -2,4-diones et leur utilisation en tant que ligands du recepteur ampa
TNSN05073A1 (fr) Quinazolinones spirocondensees nouvelles et leur utilisation comme inhibiteurs de phosphodiesterase
MA31764B1 (fr) Composés et compositions en tant que modulateurs de l'activité de gpr119
ATE483706T1 (de) Weitere heteropolycyclische verbindungen und deren verwendung als antagonisten des metabotropen glutamatrezeptors
MA27774A1 (fr) Inhibiteurs de phosphatidylinositol 3-kinase
MA30351B1 (fr) Composes de tetrahydropyridothienopyrimidine et leurs procedes d'utilisation
MA30911B1 (fr) Nouveaux derives de sulfonamide en tant qu'antagonistes de bradykinine
MA29791B1 (fr) Composes therapeutiques.
WO2010028189A3 (fr) Composés, compositions, et procédés d'utilisation, permettant de moduler les taux d'acide urique
SE0403006D0 (sv) New compounds
MA32466B1 (fr) Derives de triazole utiles pour le traitement de maladies
MA27334A1 (fr) Utilisation d'inhibiteurs de l'ikb kinase dans le traitement de la douleur
MA28747B1 (fr) Dérivés de pyridine
MA31433B1 (fr) Inhibiteurs de la p70 s6 kinase
MA30406B1 (fr) Nouveaux composes
MA31949B1 (fr) Dérivés d'aminotriazole comme agonistes d'alx
SE0300119D0 (sv) Novel compounds
MA30696B1 (fr) Derives de l'acide (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetique
MA30331B1 (fr) ANTICORPS à EFGL 7 ET LEURS PROCEDES D'UTILISATION